Introduction {#Sec1}
============

In patients with a primary intracranial tumor, cognitive deficits as well as epileptic seizures and their treatment might negatively affect health-related quality of life (HRQOL) \[[@CR3], [@CR11], [@CR32]\]. Meningiomas are the most frequently reported intracranial tumors, accounting for approximately one-third of all central nervous system tumors \[[@CR22]\]. Although the majority of meningiomas is benign, patients have long-term neurological problems that affect normal daily activities \[[@CR30]\].

We have previously shown that many patients with suspected as well as with histologically proven World Health Organization (WHO) grade I meningiomas show subtle cognitive deficits that might be attributed to the tumor itself, the surgical treatment, or the occurrence of seizures and treatment with antiepileptic drugs (AED) \[[@CR6], [@CR31]\].

Frequently, meningiomas are an incidental finding in ancillary investigations following head trauma or a routine radiological checkup (e.g., "total body MRI") \[[@CR16], [@CR24], [@CR34], [@CR35]\]. Proper selection for surgery of patients with an incidentally found meningioma is, however, hampered by lack of information concerning preoperative predictors for long-term cognitive functioning and HRQOL. For this group of patients, timing and choice of treatment remains a matter of debate.

Several studies have suggested that tumor-related edema, apart from the tumor itself and tumor-related seizures and their treatment, may have a negative impact on cognitive functioning \[[@CR15], [@CR28], [@CR29], [@CR34]\]. The reported incidence of edema in meningioma patients varies from 38 to 90% \[[@CR13], [@CR21], [@CR23], [@CR25]\].

The aim of this study is to determine whether there is an association between preoperative cerebral edema and postoperative cognitive functioning and HRQOL at least 5 months following surgery in patients with a WHO grade I meningioma.

Methods and materials {#Sec2}
=====================

Patients {#Sec3}
--------

In this cross-sectional study, we included all consecutive patients treated surgically for a meningioma between November 1, 2005 and September 31, 2007, at the VU University Medical Center, which is a tertiary referral center for primary brain tumor patients in the Amsterdam metropolitan area with a total population of approximately 2.4 million people. Excluded were patients with atypical or malignant meningioma (WHO grades II or III) and patients who suffered from one of the following medical conditions, as these may interfere with normal cognitive functioning: other central nervous system (CNS) or non-CNS malignancy, cerebrovascular pathology, congenital CNS malformations, multiple sclerosis, Parkinson's disease, organic psychosis, dementia, or schizophrenia. Furthermore, patients had to have sufficient proficiency of the Dutch language to be able to carry out the cognitive tests.

The treating physician invited the patients by letter to participate in the study. Of the 28 patients who met the inclusion criteria, 21 agreed to participate in the study; seven patients declined because they considered participation to be too burdensome. After written informed consent was obtained, an appointment was made for cognitive assessment.

Patient characteristics and preoperative symptoms are shown in Table [1](#Tab1){ref-type="table"}.Table 1Patient characteristics and pre- and postoperative symptomsPatientAgeGenderPre-operative symptomsAnatomical location of the tumorVolume of tumor (cc)Volume of edema (cc)Volume of residual tumor (cc)Symptoms 3 months after surgeryTime from surgery to assessment (months)Postoperative radiotherapy172fCranial nerve palsy (n. V, VII, VIII)Right cerebellopontine angle37.01.221.2Decrease in cranial nerve palsy27Yes252mNoneRight frontal104.535.144.5Gait disturbance caused by spinal cord tumor25Yes341fVisual field deficitRight sellar1.7.0.0None19No452fNoneRight temporal47.32.7.0None17No566fSeizuresRight frontoparietal18.934.9.0None15No642fProptosis ODRight frontotemporal3.9.01.5Decrease in proptosis13No745fMigraineRight parietal12.0.0.0None10No856mNoneRight temporal25.8.54.6None10No935fDiplopiaRight cerbellopontine angle6.1.0.0None6No1051mSeizuresLeft parietal31.914.3.0Mild dysphasia23No1166fSeizuresLeft parietal17.736.5.6None23No1249mHemiparesis rightLeft parietal31.912.1.0Seizures20No1364mHemiparesis right, dysphasiaLeft parietal3.85.3.0None14No1447fSeizuresLeft frontotemporal31.143.8.0None13No1543fSeizuresLeft frontotemporal29.246.3.0None12No1659vNoneLeft frontal4.839.1.0None11No1771mVisual loss ODSellar, midline, frontal4.6.0.0Increase in visual loss OD23No1857mVisual loss ODSellar midline7.6.0.0None17No1958vNoneOlfactory groove, frontal, midline35.525.11.0None15No2050vAnosmiaOlfactory groove, frontal, midline76.815.9.0Anosmia10No2146vVisual loss ODSOlfactory groove, frontal. L \> R64.261.52.9Decrease in visual loss ODS5No*OD* oculus dexter, *ODS* oculi dexter et sinister

Healthy controls {#Sec4}
----------------

For cognitive function, patients were individually matched with healthy controls from the Maastricht Aging Study, which comprises a large cross-sectional study into the biomedical and psychological determinants of cognitive aging of 2000 healthy individuals aged 24 to 81 years \[[@CR8]\]. For HRQOL, patient were individually matched with healthy controls from a national study that aimed to translate the Short-Form Health Survey (SF-36) for use among Dutch-speaking residents of The Netherlands \[[@CR1]\]. Patients and healthy controls were individually matched with respect to gender, age, and educational level. Educational level was assessed by a Dutch scoring system consisting of an eight-point scale, ranging from unfinished primary education (level 1) to university level (level 8) \[[@CR5]\].

The medical ethics committee of the VU University Medical Center approved the study protocol.

Study measures {#Sec5}
--------------

### Functional status {#Sec6}

Patients' capacity to carry out life's daily activities was assessed by means of the Barthel Activities of Daily Living Index \[[@CR33]\]. Scores range from 0 to 20, with higher scores indicating higher levels of functional independence. The Karnofsky Performance Status (KPS) Scale was used as an overall indicator of patients' level of physical functioning \[[@CR9]\]. KPS scores range from 0 to 100, with higher scores indicating higher levels of functioning. Patients' level of neurologic functioning was assessed by means of Neurological Functional Status Scale, with the score range from 1 to 4; higher scores represent higher levels of neurologic dysfunction \[[@CR20]\].

### Cognitive functioning {#Sec7}

A wide range of cognitive functions was assessed by means of a standardized test battery (see Appendix [1](#MOESM1){ref-type="media"} in the Supplementary Material). Individual cognitive test scores were converted into *z*-scores using the means and standard deviations (SDs) of the matched healthy controls as a reference. Subsequently, *z*-scores were transformed into the following six cognitive domains: executive functioning, working memory, verbal memory, attention, information processing speed, and psychomotor speed \[[@CR11]\]. Dysfunction in cognitive functioning was defined as a *z*-score ≥ 1.5 SD below the mean of the healthy controls. The total time required to complete the battery was approximately 60 min. After completing the battery, patients also filled in a visual analogue scale, by which patients reported the amount of effort they had to invest to complete the cognitive testing battery.

### Health-related quality of life {#Sec8}

Self-reported HRQOL was measured with the Dutch translation of the SF-36 \[[@CR1]\]. The SF-36 is composed of 36 items, organized into eight multi-item scales assessing physical functioning (PF), role limitation caused by physical health problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitation caused by emotional problems (RE), and mental health (MH). Raw scores are converted linearly to scales of 0 to 100, with higher scores representing better levels of functioning.

### Magnetic resonance imaging {#Sec9}

Magnetic resonance imaging (MRI) was performed prior to surgery for each patient. Scans were reviewed by a neuroradiologist (E.S.A.) who was not aware of the patient's medical history. Data collection included tumor characteristics (tumor volume (cc), volume of edema (cc), total volume of edema and tumor (cc), and tumor localization). Edema was defined as T2-weighted hyperintensity adjacent to the tumor or present in the parenchyma adjacent to the surgical site. If there was no T2-weighted hyperintensity adjacent to the tumor or present in the parenchyma adjacent to the surgical site, we concluded that there was no edema present (example in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). Volumetric measurement of tumor and T2-weighted hyperintensity was done using the BrainLAB iPlan® version 2.6 neuronavigation system (BrainLAB AG, Heimstetten, Germany) to seclude the meningioma.Fig. 1Magnetic resonance images. Meningioma with edema. Left image T2-weighted image; right image T1-weighted image with gadoliniumFig. 2Magnetic resonance images. Meningioma without edema. Left image T2-weighted image; right image T1-weighted image with gadolinium

Statistical analysis {#Sec10}
--------------------

We determined a non-normal distribution because of the small study group. Mann-Whitney *U* tests were used to test for differences in cognitive functioning and HRQOL between patients and healthy controls. Furthermore, Kendall's tau coefficients (two-tailed) were used to determine the associations between cognitive functioning or HRQOL and the following factors in both pre- and postoperative MRI scans: edema volume, tumor volume, and combined edema and tumor volume. In the statistical analyses performed using SPSS, version 24 for Windows, statistical significance was set at *p* \< .05 (one-sided, because of the expected deleterious effects of having a meningioma and/or edema).

Results {#Sec11}
=======

Sociodemographic and clinical characteristics {#Sec12}
---------------------------------------------

As a result of the matching procedure, patients and healthy controls did not differ significantly in age, gender, and educational level (Table [2](#Tab2){ref-type="table"}). Mean tumor volume in meningioma patients with edema was significantly larger than in meningioma patients without edema (37.4 vs 6.0 ml; *p* = .004).Table 2Sociodemographic and clinical characteristics of the study patientsMeningioma patients (*n* = 21)Healthy controls\
Cognitive functioning (*n* = 21)*p* ^a^Healthy controls\
HRQOL\
(*n* = 21)*p* ^a^Mean (SD)Mean (SD)Mean (SD)Characteristics Mean age in years^d^55.3 (10.6)56.1 (10.4).8255.9 (10.4).94 Gender, no. male (perc.)7 (33.3)9 (42.9)6 (28.6) Educational level^d^4.0 (1.8)4.0 (1.8)1.003.9 (1.9).75Premorbid intelligence Dutch adult reading test (raw scores)88.4 (14.3)n/an/aPreoperative edema^c^ Yes15n/an/a No6n/an/aTumor characteristics^b^ Tumor volume preoperative28.4 (1.7--104.5^e^)n/an/a Edema volume preoperative17.8 (0.0--61.5^e^)n/an/a Tumor volume 3 months postoperative3.6 (0.0--44.5^e^)n/an/a Edema volume 3 months postoperative0.7 (0.0--6.7^e^)n/an/aTumor localization^c^ Convexity,  With edema  Without edema13112n/an/a Skull base,  With edema  Without edema514n/an/a Orbital,  With edema  Without edema330n/an/aYears since histological diagnosis1.30 (0.52)n/an/aFunctional/performance status Karnofsky100 (80--100)^f^n/an/a Barthel20 (8--20)^f^n/an/a*HRQOL* health-related quality of life, *n/a* not applicable or not available^a^Based on *t* test comparisons between patients and healthy controls^b^Milliliters^c^Number of patients^d^Non-parametric *t* test^e^(Minimum--maximum)^f^Median (minimum--maximum)

Cognitive functioning {#Sec13}
---------------------

Patients had a significantly lower verbal memory capacity (*p* = .012) compared to healthy controls. No statistically significant differences were found between patients and healthy controls in executive functioning, working memory, attention functioning, information processing speed and psychomotor speed. Patients with edema (*n* = 15) had significantly worse cognitive functioning than patients without edema (*n* = 6) in all six cognitive domains (Table [3](#Tab3){ref-type="table"}).Table 3Cognitive functioning and health-related quality of life in meningioma patients with and without pre-operative peritumoral edemaMeningioma patients with edema (*n* = 15)Meningioma patients without edema (*n* = 6)*p*\*Clinical characteristics Mean age in years57.3 (8.9)50.5 (13.8).118 Time of assessment since histological diagnosis (years)1.3 (0.5)1.2 (0.5).697 Tumor volume pre-operative37.4 (26.9)6.0 (3.6).004^a^ Tumor volume 3 months postoperative5.0 (12.2)0.3 (0.6).286 Percentage of symptomatic patient (\#)66.7% (10)100% (6) Percentage of patients treated with radiotherapy after surgery (\#)13.3% (2)0% (0)Domains of cognitive functioning^b^ Executive functioning− .6763 (1.2945)1.0059 (0.5870).004^c^ Psychomotor speed− .6544 (1.0200).4561 (0.3593).006^c^ Working memory− .4349 (1.0145).7695 (0.6759).006^c^ Information processing− .5683 (1.2087).8458 (0.5470).004^c^ Attention− 1.0760 (2.0279).9396 (0.8111).006^c^ Verbal memory− .3504 (.8069)1.0908 (0.4257).023^c^HRQOL SF36 Scales^d^ Physical functioning76.3 (25.4)88.3 (23.8).14 Role physical55.0 (45.5)70.8 (45.9).36 Bodily pain65.9 (26.9)77.0 (29.0).34 General health63.8 (17.7)75.0 (20.9).18 Vitality62.3 (16.8)63.3 (26.4).67 Social functioning73.3 (24.0)85.4 (30.0).16 Role emotional71.1 (41.5)77.7 (40.4).75 Mental health74.9 (16.7)74.7 (28.4).88Results are mean with (standard deviation). (\#) number of patients^a^Significantly different (*p* \< .05) using Mann-Whitney *U* test (two-tailed)^b^For the neuropsychological characteristics *z*-scores derived from the mean and SD of the healthy controls are displayed^c^Significantly different (*p* \< .05) from the Meningioma patients using Mann-Whitney *U* test (one-tailed)^d^*HRQOL*, health-related quality of life; *SF36*, Short-Form Health Survey questionnaire; *M*, the mean value for each variable

Health-related quality of life {#Sec14}
------------------------------

Mann-Whitney *U* test (one-tailed) yielded no significant differences between patients and healthy controls in any of the eight multi-item scales assessing HRQOL (physical functioning *p* = .180, role limitations caused by physical health problems *p* = .479, bodily pain *p* = .237, general health *p* = .220, vitality *p* = .192, social functioning *p* = .448, role limitations caused by emotional problems *p* = .420 and mental health *p* = .391). The HRQOL of patients with edema did not differ from patients without edema in any of the eight SF-36 scales (see Table [3](#Tab3){ref-type="table"}).

Associations of tumor and edema volume with cognitive function and HRQOL {#Sec15}
------------------------------------------------------------------------

Correlational analyses showed significant associations between preoperative peritumoral edema volume and all cognitive domains postoperatively, except verbal memory and attention (Table [4](#Tab4){ref-type="table"}). Considering preoperative tumor volume, analysis showed significant associations with postoperative executive functioning, psychomotor speed, and working memory. When preoperative edema and tumor volume were combined, significant associations were found for all cognitive domains, except for attentional functioning and verbal memory. Furthermore, post hoc analysis yielded significant positive associations between the extent of preoperative edema and preoperative tumor volume (*r =* .351; *p =* .030, Kendall's tau, two-tailed).Table 4Correlations between cognitive domains, health-related quality of life and neuropathological variablesPreoperative edemaPreoperative tumor volumeCombined preoperative tumor volume and edemaDomains of cognitive functioning Executive functioning*r* = − .331\**r* = − .357\*\**r* = − .357\* Psychomotor speed*r* = − .301\**r* = − .324\**r* = − .314\* Working memory*r* = − .381\*\**r* = − .305\**r* = − .352\* Information processing*r* = − .321\**r* = − .219*r* = − .305\* Attention*r* = − .262*r* = − .219*r* = − .190 Verbal memory*r* = − .173*r* = − .152*r* = − .124HRQOL SF36 Scales Physical functioning*r* = − .221*r* = − .137*r* = − .208 Role physical*r* = − .288*r* = − .216*r* = − .306 Bodily pain*r* = − .278*r* = .051*r* = − .132 General health*r* = − .172*r* = − .000*r* = − .050 Vitality*r* = − .041*r* = .089*r* = − .089 Social functioning*r* = − .263*r* = − .237*r* = − .227 Role emotional*r* = − .142*r* = − .019*r* = − .031 Mental health*r* = − .088*r* = − .010*r* = − .040Non-parametric correlation, Kendall's tau *b* test. *r* means correlation coefficient*HRQOL SF36* health-related quality of life Short Form 36\*Correlation is significant at the p \< .05 level\*\*Correlation is significant at the *p* \< .01 level

No significant associations were established for preoperative edema, preoperative tumor volume, or the combination of edema and tumor volume with HRQOL.

Discussion {#Sec16}
==========

We assessed the association between preoperative cerebral edema and postoperative cognitive functioning and HRQOL after surgery for a WHO grade I meningioma and found that patients with preoperative edema had significantly worse cognitive functioning than meningioma patients without preoperative edema after at least 5 months' follow-up. However, there was no difference in HRQOL between both patient groups 6 months after surgery.

Little is known regarding the effects of edema on cognitive functioning of meningioma patients. Steinvorth et al. evaluated cognitive outcome in patients with skull base meningiomas after fractioned stereotactic radiotherapy and only found a transient decline in memory functioning, 1 day after treatment. The authors concluded that this decline was most likely related to an increase in pre-existing peritumoral edema due to radiotherapy \[[@CR28]\]. Tucha et al. showed that preoperative edema was not associated with cognitive functioning 4 to 9 months after surgery \[[@CR29]\]. In our study, larger volumes of preoperative edema were significantly associated with lower postoperative cognitive functioning.

Peritumoral edema in meningioma patients is considered to be vasogenic. Possible causative factors for this edema, e.g., tumor volume, tumor location, vascular supply, venous obstruction, histology, vascular endothelial growth factor (VEGF) production, and interleukin-6 expression, have been studied, but the exact mechanism of development of cerebral edema in meningioma patients remains unclear \[[@CR4], [@CR17], [@CR21], [@CR36]\]. Due to the blood-brain-barrier disruption, fluid is transferred to the extracellular space leading to disturbances of synaptic functioning and signal conduction across axons and dendrites \[[@CR28]\]. White matter is particularly vulnerable to vasogenic edema, which tends to extend along neighboring fiber tracks. Furthermore, edema might lead to mass effect and thus to further compression of surrounding brain, sometimes resulting in local ischemia. These mechanisms may lead to cognitive deficits.

Cognitive deficits in brain tumor patients might also be attributed to surgical treatment, to the occurrence of seizures, to the treatment with antiepileptic drugs, or to the tumor itself \[[@CR6], [@CR11], [@CR12]\]. Studies describing the association between tumor volume and the extent of peritumoral edema are inconsistent \[[@CR2], [@CR7], [@CR10], [@CR27]\]. In a previous study, we have shown that the addition of radiotherapy after surgery does not seem to have significant early (median follow up 3.3 years) detrimental impact on an already impaired cognitive functioning in meningioma patients \[[@CR31]\]. We found positive associations between preoperative tumor volume and postoperative cognitive functioning. Furthermore, post hoc analysis yielded positive associations between the extent of preoperative edema and preoperative tumor volume. Although the association between preoperative edema and cognitive functioning was stronger than the association between preoperative tumor volume and cognitive functioning, tumor volume is a possible confounding factor for the association found between edema and cognitive performance. Regarding the mechanical effects exerted by both the tumor and the surrounding edema, it is most likely that the combination of these volumes might have negatively affected neurocognitive outcome. A relatively recent study also showed larger tumor volumes to be associated with poorer neurocognitive outcomes \[[@CR14]\]. Considering the fact that surgery led to a significant reduction in tumor and edema mass (Table [2](#Tab2){ref-type="table"}), we do not expect postoperative residual tumor and edema to affect cognition. Although our study shows that preoperative peritumoral edema is associated with limitations in cognitive functioning after surgery, this preoperative peritumoral edema does not seem to affect HRQOL. A recent systematic review by Najafabadi et al. describes both worse and better HRQOL scores in meningioma patients compared with healthy controls. Based on the available results, they conclude that, in general, meningioma patients have a clinically relevant worse HRQOL than healthy controls \[[@CR19]\]. In our study, HRQOL in treated meningioma patients was comparable to that of the general population. A correlation between preoperative edema and HRQOL was not found. As far as we know, the effect of peritumoral edema and tumor volume on HRQOL has not been studied in meningioma patients before. The relatively unaffected HRQOL in our study may be explained by the fact that patients might have adapted to their postsurgical functioning or that a patient's understanding or perception of HRQOL has changed over time, the so-called response shift \[[@CR26]\]. Furthermore, Waagemans et al. showed that HRQOL particularly is compromised in meningioma patients with major cognitive deficits and those using AEDs \[[@CR32]\].

Some shortcomings of this study need to be addressed. The number of patients is too small for subgroup analyses. The effect of epilepsy burden (i.e., AED use and seizure frequency), localization and lateralization of the tumor, and treatment-related factors on cognitive functioning and HRQOL could therefore not be studied. Pre- and postoperative amount of tumor may also influence cognition. Multivariate analysis to correct for tumor volume could not be performed, because of the small amount of patients.

Furthermore, since preoperative cognitive assessment is lacking, we could not analyze whether surgery itself also influences cognition. The effects of surgery on cognition in meningioma patients are not clear. Markovic et al. suggest that postoperative complications are more frequent in meningioma patients with peritumoral edema, which indicates the possibility of cognitive decline after surgery \[[@CR18]\]. However, Tucha et al. indicate postoperative improvements in attentional functions in meningioma patients \[[@CR29]\].

Although our results suggest that meningioma patients with larger volumes of preoperative peritumoral edema are at risk of experiencing longer-term cognitive deficits, future research efforts should focus on underlying causes and the question whether (early) reduction of peritumoral edema results in an improvement of cognition. Perhaps peritumoral edema in otherwise asymptomatic patients should prompt earlier surgery, or early treatment with medication (e.g., steroids, angiogenesis inhibitors) in an effort to prevent, or ameliorate, longer-term cognitive functioning. To meet this aim, prospective studies with larger patient groups including pre- and postoperative assessment are needed.

Conclusion {#Sec17}
==========

Our results suggest that meningioma patients with larger volumes of preoperative peritumoral edema may be at risk of experiencing limitations in longer-term cognitive functioning. This knowledge is useful for neurologists and neurosurgeons treating patients with a meningioma, but more studies regarding the effect of peritumoral edema on cognitive functioning in meningioma patients are necessary.
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